News
The worldwide dash to get goods to the U.S. ahead of President Trump's tariffs has been distorting trade patterns all year.
6h
Barchart on MSNThis Pharma Stock Is Still a ‘Strong Buy’ Despite Trump’s Plans to Lower Drug PricesWhile the early week buzz centered around the U.S.-China trade agreement, another critical development unfolded quietly but ...
Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...
Last year, the Biden administration set limits on PFAS in drinking water systems. Donald Trump’s EPA is planning to ...
Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.
COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...
Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...
Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.
Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.
For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
Health-care companies rose sharply after President Trump signed an executive order designed to lower what Americans pay for prescription drugs that offered pharmaceutical companies room for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results